COSMOS Pharmaceutical Corporation (3349.T)

9053.0035.00 (-0.39%)

COSMOS Pharmaceutical Corporation (3349.T) stock comprehensive Valuation Ratios Analysis including PE, PB, PS, EV/EBITDA. Analyze if 3349.T stock is undervalued compared to peers/competitors, industry and sector standards or based on Value Investing Principles.

Low Bankruptcy RiskLow ProfitabilityEfficient OperationsModerate GrowthModerate QualityAdequate Dividend ProfileIndustry Rank: 67.57%Sector Rank: 75.68%

JPX - Healthcare - Medical - Pharmaceuticals | Market Cap: 717.52B | Next Earnings Date: 14 Oct 2025

Day's Range

8935.00 - 9125.00

52-Week Range

6347.00 - 10045.00

Volume

380.0K / 335.9K (Avg.)

P/E Ratio | EPS

23.15 | 391.09

Trending:

3349.T Valuation Analysis - Compare Against 3391.T

Comparison against 3391.T

None 3391.T 3141.T 3088.T 2127.T 9843.T

These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.

Price-to-Earnings Ratio (P/E)

26.03

Increased from previous period

P/E above 1.5x 3391.T's 15.66. Jim Chanos would check for potential multiple compression risks.

Price-to-Sales Ratio (P/S)

2.80

Increased from previous period

P/S 1.25-1.5x 3391.T's 1.99. Martin Whitman would scrutinize if premium reflects better growth prospects.

Price-to-Book Ratio (P/B)

3.15

Increased from previous period

P/B above 1.5x 3391.T's 1.89. Michael Burry would check for potential asset overvaluation.

Price-to-Free Cash Flow Ratio

73.89

Increased from previous period

P/FCF 1.1-1.25x 3391.T's 63.23. Bill Ackman would demand evidence of superior reinvestment opportunities.

Price-to-Operating Cash Flow Ratio

73.89

Increased from previous period

P/OCF 1.1-1.25x 3391.T's 63.23. Bill Ackman would demand evidence of superior operating efficiency.

Price-to-Fair Value

3.15

Increased from previous period

Fair value ratio above 1.5x 3391.T's 1.89. Michael Burry would check for mean reversion risks.

Earnings Yield

0.96%

Decreased from previous period

Earnings yield 50-75% of 3391.T's 1.60%. Martin Whitman would scrutinize if lower yield reflects better quality.

Free Cash Flow Yield

1.35%

Decreased from previous period

FCF yield 75-90% of 3391.T's 1.58%. Bill Ackman would demand evidence of superior growth prospects.

Select Chart Metric:

3349.T Valuation Analysis - Compare Against 3391.T

Comparison against 3391.T

None 3391.T 3141.T 3088.T 2127.T 9843.T

Price-to-Earnings Ratio (P/E)

26.03

Increased from previous period

P/E above 1.5x 3391.T's 15.66. Jim Chanos would check for potential multiple compression risks.

Price-to-Sales Ratio (P/S)

2.80

Increased from previous period

P/S 1.25-1.5x 3391.T's 1.99. Martin Whitman would scrutinize if premium reflects better growth prospects.

Price-to-Book Ratio (P/B)

3.15

Increased from previous period

P/B above 1.5x 3391.T's 1.89. Michael Burry would check for potential asset overvaluation.

Price-to-Free Cash Flow Ratio

73.89

Increased from previous period

P/FCF 1.1-1.25x 3391.T's 63.23. Bill Ackman would demand evidence of superior reinvestment opportunities.

Price-to-Operating Cash Flow Ratio

73.89

Increased from previous period

P/OCF 1.1-1.25x 3391.T's 63.23. Bill Ackman would demand evidence of superior operating efficiency.

Price-to-Fair Value

3.15

Increased from previous period

Fair value ratio above 1.5x 3391.T's 1.89. Michael Burry would check for mean reversion risks.

Earnings Yield

0.96%

Decreased from previous period

Earnings yield 50-75% of 3391.T's 1.60%. Martin Whitman would scrutinize if lower yield reflects better quality.

Free Cash Flow Yield

1.35%

Decreased from previous period

FCF yield 75-90% of 3391.T's 1.58%. Bill Ackman would demand evidence of superior growth prospects.

Select Chart Metric: